Strides Pharma Science Limited – SWOT Analysis

Strengths Strong Global Generic Presence – Significant presence in regulated markets like the US, Europe, Australia, and Africa supports revenue diversification. Specialized Product Portfolio – Focus on soft gel capsules, injectables, sterile products, and complex generics improves margins. Weaknesses US Market Dependence – High exposure to the US generic market increases pricing and regulatory risk. Regulatory Compliance Risk – Pharma manufacturing remains vulnerable to USFDA observations and compliance issues. Debt and Restructuring History – Past financial restructuring and leverage concerns affect investor sentiment. Opportunities Complex Generics Expansion – Higher-margin niche products can improve long-term profitability. China+1 API and Pharma Shift – Global sourcing diversification benefits Indian pharma exporters. Institutional & Emerging Market Growth – Africa and other emerging markets provide strong expansion opportunities. Threats USFDA Regulatory Action – Warning letters or import alerts can significantly affect business. Pricing Pressure in US Generics – Strong competition may reduce margins. Currency Volatility – Forex fluctuations impact export realization and import costs. Raw Material Dependence – API sourcing disruptions or cost increases may pressure profitability. Competition from Global Generic Players – Large pharma companies create strong market pressure. Disclaimer AASHISH SEBI RA INH000013174 This analysis is only for educational and informational purposes and should not be considered as buy/sell recommendation. Investors should consult their financial advisor before making any investment decision. Stock market investments are subject to market risks. Past performance does not guarantee future results.